Robin R. Frey

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Loren Lasko, Clarissa G. Jakob, Rohinton Edalji et al. · Nature · 2017 · 858 citations · Full text

Medicine, Cancer Biology, Oncology +8

Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors

Yujia Dai, Yan Guo, Robin R. Frey et al. · Journal of Medicinal Chemistry · 2005 · 152 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Trifluoromethyl ketones as inhibitors of histone deacetylase

Robin R. Frey, Carol K. Wada, Robert B. Garland et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 147 citations · Full text

Life Sciences, Medicinal Chemistry, Molecular Biology +13

Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X_L Inhibitor

Le Wang, George Doherty, Andrew S. Judd et al. · ACS Medicinal Chemistry Letters · 2020 · 136 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC)

Michael L. Curtin, Robert B. Garland, H. Robin Heyman et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 113 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +13